Novo Nordisk sticks to cautious obesity sales goal
Despite an optimistic stock market, Novo Nordisk is not changing its modest guidance of more than doubling its obesity drug sales by 2025.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Novo Nordisk is stubbornly mantaining its cautious goal for obesity sales in spite of pervasive optimism on the stock market, according to Danish media Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly welcomes competition for cheap insulin in US
For subscribers
Novo Nordisk wants to innovate in new ways to find cures
For subscribers
